東洋美人ホールディングス
TOYO   BIJIN   HOLDINGS
III-3 · INVESTMENT PORTFOLIO

Investment Portfolio

Where the Group's Substance Lives

Toyo Bijin Capital currently holds 8 companies, the technology of 3 of which has already flowed back into the Group's core business — forming the closed loop of "capital returning to science."

Current Portfolio
8 companies
Reciprocated to the Group
3 companies
2027 Expansion
12 companies
Per-Investment Scale
<$12,000,000
PORTFOLIO · 8 COMPANIES

Four Strategic Directions · Eight Investment Holdings

I
Regenerative Medicine & Stem Cell
Regenerative Medicine & Stem Cell
01

Regenerative Medicine Startup

Regenerative Medicine Startup
Stage
Series B · 2020 Lead
Stake
18.5%
Focus
Skin cell regeneration and epidermal stem cell cultivation
Synergy with the Group
Jointly developed the stem cell culture extract technology with the Kyoto Institute.
02

Cell Cultivation Platform Company

Stem Cell Cultivation Process
Stage
Series A · 2019 Lead
Stake
22.0%
Focus
High-density autologous stem cell cultivation process
Synergy with the Group
GMP factory process translation; Kyoto pilot-line completed.
★ Reciprocated to the Group
03

Skin Regeneration Tech Company

Signal Peptide Research
Stage
Seed → Series A · 2017 First Investment
Stake
31.0%
Focus
Multi-repair signal peptide synthesis and stabilization
Synergy with the Group
Stem cell culture extract technology already adopted in the Maison Bijin Revitalizing Serum line.
II
Women's Wellness Frontier
Women's Wellness Frontier
★ Reciprocated to the Group
04

Women's Health Diagnostic Lab

Intimate Repair Signal Peptides
Stage
Series A → B · 2018 First / 2022 Follow-on
Stake
24.0%
Focus
Multi-signal-peptide research for women's intimate repair
Synergy with the Group
Repair signal peptides have become the core ingredient of the 12th-generation revitalizing complex, launching with the Bijin Privé flagship in spring 2026.
05

French Women's HealthTech Company

Gynecological Clinical Data
Stage
Series B Minority · 2023
Stake
12.5%
Focus
Vaginal microecology testing and women's hormonal-rhythm data
Synergy with the Group
Bijin Privé's international gateway; anonymized data shared with the Group's 12 clinical projects.
III
Sustainable Beauty Materials
Sustainable Beauty Materials
★ Fully Acquired
06

Sustainable Packaging Tech Company

Biodegradable Packaging
Stage
Full Acquisition · 2022 / 11
Stake
100%
Focus
Biodegradable packaging materials R&D
Synergy with the Group
Operating independently as the Group's packaging R&D center; helping the Group meet its 2028 packaging circularity commitment 3 years ahead of schedule.
07

Green Chemistry Materials Company

Green Chemistry Solvents
Stage
Series A · 2021
Stake
19.5%
Focus
Water-based processes replacing traditional organic solvents
Synergy with the Group
Core technology partner for the Kyoto Institute's water-based process program.
IV
Clinical Data & AI
Clinical Data & AI
★ Reciprocated to the Group
08

AI Skin Data Analytics Company

Skin Data Analytics
Stage
Series A · 2020
Stake
27.0%
Focus
AI-assisted clinical skin data analysis and machine learning
Synergy with the Group
The data analytics platform has been deployed in the validation workflow of the Kyoto Institute's 12 clinical projects.
★ RECIPROCAL TO THE GROUP

Capital Returns to Science · Three Companies Feeding Back

We invest not for a financial exit, but to plant the seed of science back into the Group's core business. The technologies of three companies have already landed in Group products and research workflows.

Skin Regeneration Tech Company
Technology
Stem Cell Culture Extract
Lands in
Core of Maison Bijin Revitalizing Serum Line
Women's Health Diagnostic Lab
Technology
Multi-Repair Signal Peptides
Lands in
Core of the 12th-Generation Revitalizing Complex
AI Skin Data Analytics Company
Technology
AI Skin Data Analytics
Lands in
Validation Workflow of the Kyoto Institute's 12 Clinical Projects
2027 EXPANSION

Expanding from 8 to 12

Four new holdings to be added over the next three years — concentrated in the two axes of internal nutrition and digital health, forming cross-business synergy with the Toyo Wellness segment.

  • Internal Nutrition ・ Two holdings in synergy with Toyo Wellness
  • Digital Health ・ Two holdings in skin and hormonal-rhythm monitoring
  • Per-Investment Scale ・ <$15M
KEY METRICS
Per-Investment Scale
<$12,000,000
Group Holdings Valuation
≈$245M
Average Holding Period
8.5 years
Aggregate IRR
32.4%

The portfolio information presented on this page is for reference only. The definitive investment targets, stages, and amounts are governed by the Group's annual report and the public disclosures of Toyo Bijin Capital.

Return to Investment Strategy →See Reciprocated Products →